Abingdon Health rolling out saliva-based pregnancy test

The AIM-traded firm said the product would provide women with an enhanced user experience, delivering high accuracy for early pregnancy detection, using patented saliva technology instead of traditional urine tests.

It said Salistick allows for convenient testing anywhere and at any time, fostering the opportunity to share the testing experience with partners and loved ones.

Salignostics, an Israel-based developer of saliva-based diagnostic tests, had entrusted Abingdon as the exclusive distributor of Salistick in the UK and Ireland.

Abingdon had provided distribution support, and offered contract development services to Salignostics, aiding in the scaling-up of the Salistick product for manufacturing.

The company said it would continue to provide contract manufacturing services to Salignostics in the future.

Abingdon added that it was partnering with retailer Superdrug for the launch of Salistick.

Initially, the product would be rolled out across 400 Superdrug stores, and will be available for purchase on Superdrug.com.

Additionally, Abingdon would introduce Salistick through its direct-to-consumer e-commerce channel, ‘Abingdon Simply Test’.

The product would be co-branded as ‘Abingdon Simply Test’, expanding the range of self-tests available under the brand line to more than 15.

Abingdon said it was aiming to continuously broaden its selection of self-tests by partnering with companies like Salignostics in a bid to provide consumers with the best novel self-test technologies available in the market.

“We are delighted to announce the launch of Salistick, initially across 400 Superdrug stores and at Superdrug.com,” said chief executive officer Chris Yates.

“This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the experience to be shared with a partner and other loved ones.

“We are pleased to have supported our partner Salignostics through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward.”

At 1058 BST, shares in Abingdon Health were up 8.88% at 16p.

Reporting by Josh White for Sharecast.com.